Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | PREP | P48147 | 1/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23536765 | 0.90 | KMT2A (0.49) | HDAC3HDAC1HDAC2KMT2ACES2 | |
| SCHEMBL28432192 | 0.82 | HDAC1 (0.46) | HDAC3HDAC1HDAC2CES2CES1 | |
| SCHEMBL3910906 | 0.82 | CYP2C19 (0.48) | HDAC3HDAC1HDAC2KMT2ACYP2C19 | |
| SCHEMBL164708 | 0.76 | CES2 (0.54) | HDAC1PREPCRBNKMT2ACES2 | |
| SCHEMBL29953271 | 0.74 | HDAC3 (0.54) | HDAC3HDAC1HDAC2CYP2C19NPC1 | |
| SCHEMBL3920568 | 0.74 | HDAC3 (0.54) | HDAC3HDAC1HDAC2CYP2C19NPC1 | |
| SCHEMBL3908300 | 0.74 | HDAC3 (0.54) | HDAC3HDAC1HDAC2CYP2C19NPC1 | |
| SCHEMBL716489 | 0.74 | CES2 (0.50) | KMT2ACES2CES1NPC1RAB9A | |
| SCHEMBL22041535 | 0.73 | CRBN (0.57) | PREPCRBNKMT2ANPC1RAB9A | |
| SCHEMBL4608676 | 0.73 | PPIA (0.50) | HDAC2CES2CES1CYP2C19NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524837-B2 | Benzotriazapinone salts and methods for using same | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-28 | — | — | US | disclosed |
| CN-100348196-C | Benzotriaza * as gastrin and cholecystokinin receptor ligands | BLACK JAMES FOUNDATION (GB) | 2007-11-14 | — | — | CN | disclosed |
| WO-2006129120-A9 | BENZOTRIAZEPINONE DERIVATIVES | JAMES BLACK FOUNDATION (GB) | 2007-03-22 | — | — | WO | disclosed |
| WO-2006129120-A2 | BENZOTRIAZEPINONE DERIVATIVES | JAMES BLACK FOUNDATION (GB) | 2006-12-07 | — | — | WO | disclosed |
| US-20060003993-A1 | Benzotriazepnes as gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2006-01-05 | — | — | US | disclosed |
| EP-1443934-B1 | BENZOTRIAZEPINES AS GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 2005-04-20 | — | — | EP | disclosed |
| CN-1585643-A | Benzotriazepines as gastrin and cholecystokinin receptor ligands | BLACK JAMES FOUNDATION (GB) | 2005-02-23 | — | — | CN | disclosed |
| US-20050026911-A1 | Benzotriazapinone salts and methods for using same | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-03 | — | — | US | disclosed |
| WO-2004101533-A1 | 1, 3, 4-BENZOTRIAZEPIN-2-ONE SALTS AND THEIR USE AS CCK RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA, N.V. (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-1443934-A1 | BENZOTRIAZEPINES AS GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003041714-A1 | BENZOTRIAZEPINES AS GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026911-A1 | Benzotriazapinone salts and methods for using same | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC13A3, CLIC1 | HDAC3 918/4885HDAC1 2567/4885HDAC2 2817/4885 |
| US-20060003993-A1 | Benzotriazepnes as gastrin and cholecystokinin receptor ligands | CCKBR, GRPR, CCKAR | HDAC3 954/4885HDAC1 1117/4885HDAC2 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.